Ocular implant with therapeutic agents and methods thereof

• US 8,348,877 B2
• Filed: 05/03/2010
• Issued: 01/08/2013
• Est. Priority Date: 04/14/2000
• Status: Expired due to Fees

• Current Assignee: DOSE Medical Corporation (Glaukos Corporation)
• Original Assignee: DOSE Medical Corporation (Glaukos Corporation)
• Inventors: Tu, Hosheng, Niksch, Barbara, Haffner, David, Smedley, Gregory, Gharib, Morteza, Bergheim, Olav B
• Primary Examiner(s): DEAK, LESLIE R
• Application Number:
  US12/772,889
• Publication Number:
  US 20100234790A1
• Time in Patent Office: 981 Days
• Field of Search: 604 7- 10, 604/6.16, 604264-266, 604/27, 604/43, 604/521, 604/522, 604/93.01, 210/645, 606106-109, 623/1.42, 623/4.1, 623/23.7, 623/23.64
• US Class Current: 604/8
• CPC Class Codes: A61F 2250/0067 Means for introducing or releasing pharmaceutical products into the body
• CPC Class Codes: A61F 9/0017 implantable in, or in contact with, the eye, e.g. ocular inserts
• CPC Class Codes: A61F 9/00781 Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment drainage implants in general A61M27/002
• CPC Class Codes: A61L 2300/258 Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids
• CPC Class Codes: A61L 2300/41 Anti-inflammatory agents, e.g. NSAIDs
• CPC Class Codes: A61L 2300/414 Growth factors
• CPC Class Codes: A61L 2300/416 Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
• CPC Class Codes: A61L 2300/42 Anti-thrombotic agents, anticoagulants, anti-platelet agents
• CPC Class Codes: A61L 2430/16 for reconstruction of eye parts, e.g. intraocular lens, cornea
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61M 27/002 Implant devices for drainage of body fluids from one part of the body to another intraocular A61F9/00781; middle ear A61F11/202

Abstract

Implants and methods for treating ocular disorders are provided. One method involves introducing an implant into an anterior chamber of an eye such that at least a distal end of the implant is temporarily in the anterior chamber. The implant is implanted into eye tissue adjacent the anterior chamber. A therapeutic agent is eluted from the implant into at least one of the anterior chamber, a physiologic outflow pathway of the eye, and a space adjacent a choroid of the eye. The therapeutic agent can be an antiproliferative agent, an anti-inflammatory drug, or a compound for treating glaucoma or ocular hypertension. The therapeutic agent can be contained within the implant or coated on the implant.

Claims

1. A method of treating an ocular disorder, comprising:

introducing an implant into an anterior chamber of an eye such that at least a distal end of the implant is temporarily in the anterior chamber;

implanting the implant into eye tissue adjacent the anterior chamber such that a proximal end of the implant resides in the anterior chamber following implantation; and

eluting a therapeutic agent from the implant into at least one of the anterior chamber, a physiologic outflow pathway of the eye, and a space adjacent a choroid of the eye.

2. The method of claim 1, wherein the therapeutic agent comprises an antiproliferative agent or an anti-inflammatory drug.

3. The method of claim 1, wherein the therapeutic agent comprises a compound for treating glaucoma or ocular hypertension.

4. The method of claim 1, wherein the therapeutic agent is contained within the implant.

5. The method of claim 1, wherein the therapeutic agent is coated on the implant.

6. A method of treating an ocular disorder, comprising:

forming an incision in an eye;

inserting an implant through the incision into an anterior chamber of the eye such that at least a distal end of the implant is temporarily in the anterior chamber;

implanting the implant into eye tissue such that a proximal end of the implant resides in the anterior chamber following implantation; and

eluting a therapeutic agent from the implant into at least one of the anterior chamber, a physiologic outflow pathway of the eye, and a space adjacent a choroid of the eye.

7. The method of claim 6, wherein the therapeutic agent comprises an antiproliferative agent or an anti-inflammatory drug.

8. The method of claim 6, wherein the therapeutic agent comprises a compound for treating glaucoma or ocular hypertension.

9. The method of claim 6, wherein the therapeutic agent is contained within the implant.

10. The method of claim 6, wherein the therapeutic agent is coated on the implant.

11. A method of treating an ocular disorder, comprising:

introducing an implant into an anterior chamber of an eye such that at least a distal end of the implant is temporarily in the anterior chamber;

placing the implant in contact with a choroid of the eye by advancing the distal end of the implant into eye tissue such that a proximal end of the implant resides in the anterior chamber following implantation; and

eluting a therapeutic agent from the implant into at least one of the anterior chamber, a physiologic outflow pathway of the eye, and a space adjacent the choroid.

12. The method of claim 11, wherein the therapeutic agent comprises an antiproliferative agent or an anti-inflammatory drug.

13. The method of claim 11, wherein the therapeutic agent comprises a compound for treating glaucoma or ocular hypertension.

14. The method of claim 11, wherein the therapeutic agent is contained within the implant.

15. The method of claim 11, wherein the therapeutic agent is coated on the implant.

16. A method of treating an ocular disorder, comprising:

providing an implant having at least one anchor;

introducing the implant into an anterior chamber of an eye such that at least a distal end of the implant is temporarily in the anterior chamber;

inserting at least a portion of the implant into eye tissue at an implantation site;

using the anchor to retain the implant at the implantation site such that a proximal end of the implant resides in the anterior chamber following implantation; and

eluting a therapeutic agent from the implant into at least one of the anterior chamber, a physiologic outflow pathway of the eye, and a space adjacent a choroid of the eye.

17. The method of claim 16, wherein the therapeutic agent comprises an antiproliferative agent or an anti-inflammatory drug.

18. The method of claim 16, wherein the therapeutic agent comprises a compound for treating glaucoma or ocular hypertension.

19. The method of claim 16, wherein the therapeutic agent is contained within the implant.

20. The method of claim 16, wherein the therapeutic agent is coated on the implant.